Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12300565 | 0.91 | PTPN1 (0.33) | PTPN1NR1H2NR1H3HCRTR2HSD11B1 | |
| SCHEMBL19078443 | 0.87 | ALDH1A1 (0.32) | PTPN1NR1H2NR1H3HCRTR2HSD11B1 | |
| SCHEMBL29280764 | 0.83 | SMYD2 (0.35) | PTPN1NR1H2NR1H3HCRTR2STS | |
| SCHEMBL25366552 | 0.83 | SMYD2 (0.35) | PTPN1NR1H2NR1H3HCRTR2STS | |
| SCHEMBL12248021 | 0.82 | NR1H2 (0.35) | PTPN1NR1H2NR1H3HSD11B1STS | |
| SCHEMBL15388623 | 0.81 | NR1H2 (0.34) | PTPN1NR1H2NR1H3HSD11B1STS | |
| SCHEMBL14857161 | 0.81 | NR1H2 (0.34) | PTPN1NR1H2NR1H3HSD11B1STS | |
| SCHEMBL3557230 | 0.81 | PTPN1 (0.41) | PTPN1NR1H2NR1H3HSD11B1STS | |
| SCHEMBL1662643 | 0.81 | PTPN1 (0.41) | PTPN1NR1H2NR1H3HSD11B1STS | |
| SCHEMBL1662641 | 0.81 | PTPN1 (0.41) | PTPN1NR1H2NR1H3HSD11B1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4359402-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117813298-A | Imidazole indazole compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240092758-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2024-03-21 | — | — | US | disclosed |
| WO-2022272020-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092758-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PTPN1 204/4885NR1H2 2644/4885NR1H3 3165/4885 |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | JAK1, JAK3, JAK2 | PTPN1 204/4885NR1H2 2644/4885NR1H3 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.